Skip to main content
HighTide Therapeutics, Inc. logo

HighTide Therapeutics, Inc. — Investor Relations & Filings

Ticker · 2511 HKEX Manufacturing
Filings indexed 99 across all filing types
Latest filing 2026-05-04 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2511

About HighTide Therapeutics, Inc.

http://www.hightidetx.com

HighTide Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative, multifunctional, multi-targeted therapies. The company is dedicated to addressing unmet needs within the spectrum of inter-related chronic metabolic diseases, specifically emphasizing Cardiovascular-Kidney-Metabolic (CKM) conditions. HighTide's therapeutic strategy targets diseases driven by underlying mechanisms such as insulin resistance and chronic inflammation. The product pipeline includes five candidates covering nine indications in metabolic and digestive diseases. The lead candidate, HTD1801, is currently being advanced in chronic metabolic diseases, including MASH (Metabolic dysfunction-associated steatohepatitis), Type 2 Diabetes Mellitus (T2DM), Obesity, Primary Sclerosing Cholangitis (PSC), and Chronic Kidney Disease (CKD), utilizing its dual mechanism of action.

Recent filings

Filing Released Lang Actions
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Regulatory Filings
2026-05-04 English
CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTORS AND CHANGES IN COMPOSITION OF BOARD COMMITTEES
Regulatory Filings
2026-05-04 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings
2026-05-04 English
2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
Regulatory Filings
2026-04-29 English
2025 ANNUAL REPORT
Regulatory Filings
2026-04-29 English
CONNECTED TRANSACTION THE LOAN AGREEMENT
Capital/Financing Update Classification · 1% confidence The document is a formal announcement under the Hong Kong Listing Rules describing a connected transaction, namely the company’s loan agreement (a financing arrangement) with its executive director. It details the principal terms of the loan facility, interest rate, purpose, and regulatory implications under Chapter 14A. There is no indication of earnings, share issuance, legal proceedings, or an annual report—rather it is an update on a financing activity (the provision of a loan). This aligns with the Capital/Financing Update category.
2026-04-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.